AWARE for All

February 22, 2016

The Center for Information and Study on Clinical Research Participation (CISCRP) is pleased to announce that its first international AWARE for All event will be held in the UK on 7 March, 2016 from 17:00 to 20:00 at London's Camden Centre on Euston Road.

This complementary educational event and health fair is designed to improve understanding about clinical research participation and promote dialogue by connecting patients, researchers, and members of the general public in the local community.

Ken Getz, Founder and Chairman of the Board at CISCRP said: "Medical treatments and understanding about disease cannot advance without patient participation and support from the general public - yet, patient willingness to participate in clinical trials in Europe is waning and general awareness and knowledge about clinical research is very low. The recent tragedy in France has also raised concerns about the safety, risks and benefits of taking part in clinical trials. These are among the topics that we are here to address. The launch of our first international event in London reflects our aim to empower and educate the British public and patient communities to make more informed decisions about clinical research."

At the event, which is being run in collaboration with the European Patients' Academy on Therapeutic Innovation (EUPATI), the European Patients Forum, and Merck, participants can take advantage of free health screenings & hear presentations by prominent doctors and researchers on current research advancements in oncology, psychiatry, respiratory, and Alzheimer's disease.

Keynote speaker Simon Denegri from the National Institute for Health Research (NIHR) and Chair of INVOLVE said: "A recent survey conducted by the NIHR Clinical Research Network showed that 95% of people feel it's important to them that the NHS carries out clinical research but less than 21 per cent said they would feel very confident about asking their doctor about opportunities".

He continued: "I am delighted to be speaking at the first London AWARE for All event. In aiming to break down the barriers for UK citizens in understanding and accessing information and opportunities in clinical research it builds on the work that NIHR has pioneered with its 'Ok to ask' campaign. This is vitally important in order to increase confidence, knowledge and ultimately participation in clinical research which is essential for future medical advancement in the UK."

Whilst AWARE for All London can be attended by anyone, advanced registration is strongly encouraged through the website or by calling +44 (0) 1753 833348.

The Center for Information and Study (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process. CISCRP provides free education and outreach to the general public and patient communities. Visit for more information or to support CISCRP's educational initiatives.

Editor's Note

Community collaborators include: Alzheimer's Society, the Association of Clinical Research Professionals, the Association of Medical Research Charities, Bloodwise, The Camden Outreach, DrugDev, European Patients' Forum, iCAN/KIDS, Imperial College London, Institute of Child Health, Kings College, London Cancer, Myeloma Patients Europe, Parkinson's UK, Patient Led Research Hub, Solutions 4 Health, Stop Smoking, Synexus, TrialReach, University College London, and many other prominent collaborators.

Funding for this event has been provided by Merck, the Association of Clinical Research Professionals, and local sponsors. The Camden Outreach will provide free NHS health checks to Camden residents and individuals with GPs in Camden, as well as referrals to Smokefreelife Camden, which includes a FREE Stop Smoking service with Nicotine Replacement Therapy and support. A number of exhibits will also be onsite, providing information and resources.


Censuswide consumer poll of 3,000 people in England, commissioned by National Institute for Health Research (NIHR) Clinical Research Network in September 2014. Available at:

Ketchum UK

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to